CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms by Meyer, Sara C., Keller, Matthew D., Chiu, Sophia, Koppikar, Priya, Guryanova, Olga A., Rapaport, Franck, Xu, Ke, Manova, Katia, Pankov, Dmitry, O’Reilly, Richard J., Kleppe, Maria, McKenney, Anna Sophia, Shih, Alan H., Shank, Kaitlyn, Ahn, Jihae, Papalexi, Eftymia, Spitzer, Barbara, Socci, Nick, Viale, Agnes, Mandon, Emeline, Ebel, Nicolas, Andraos, Rita, Rubert, Joëlle, Dammassa, Ernesta, Romanet, Vincent, Dölemeyer, Arno, Zender, Michael, Heinlein, Melanie, Rampal, Raajit, Weinberg, Rona Singer, Hoffman, Ronald, Sellers, William R., Hofmann, Francesco, Murakami, Masato, Baffert, Fabienne, Gaul, Christoph, Radimerski, Thomas, Levine, Ross L.

Get full text